Cardiac Manifestations in the Antiphospholipid Syndrome

Rheumatic Disease Clinics of North America

Volumn 32, Issue 3, 2006, Pages 491-507

  Tenedios, Felicia ^a   Erkan, Doruk ^a   Lockshin, Michael D ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; BOSENTAN; CORTICOSTEROID; ENDOTHELIN RECEPTOR ANTAGONIST; GADOLINIUM; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; PEPTIDE; PROSTACYCLIN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; BIOPROSTHESIS; CARDIOVASCULAR SURGERY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY THROMBOSIS; DIAGNOSTIC PROCEDURE; DOPPLER ECHOCARDIOGRAPHY; HEART DISEASE; HEART VENTRICLE FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; INTRACARDIAC THROMBOSIS; MITRAL VALVE DISEASE; MORTALITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RHEUMATIC DISEASE; SURGICAL TECHNIQUE; SYSTEMIC LUPUS ERYTHEMATOSUS; VALVULAR HEART DISEASE; VEGETATION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CARDIAC SURGICAL PROCEDURES; HEART; HEART DISEASES; HUMANS; MYOCARDIUM; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE;

EID: 33746336647     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2006.05.008     Document Type: Review

References (70)

1. Espinola Zavaleta N., Montes R.M., Soto M.E., et al. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol 31 (2004) 2402-2407
2. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 10 (2002) 752-763
3. Salmon J.E., and Girardi G. The role of complement in the antiphospholipid syndrome. Curr Dir Autoimmun 7 (2004) 133-148
4. Mackworth-Young C.G. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 136 3 (2004) 393-401
5. Meroni P.L., Borghi M.O., Raschi E., et al. Inflammatory response and the endothelium. Thromb Res 114 5-6 (2004) 329-334
6. Cervera R., Piette J.C., Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 4 (2002) 1019-1027
7. Lockshin M., Tenedios F., Petri M., et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 12 7 (2003) 518-523
8. Tincani A., Biasini-Rebaioli C., Cattaneo R., et al. Nonorgan specific autoantibodies and heart damage. Lupus 14 9 (2005) 656-659
9. Krause I., Lev S., Fraser A., et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 64 10 (2005) 1490-1493
10. Hojnik M., George J., Ziporen L., et al. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93 8 (1996) 1579-1587
11. Khamashta M.A., Cervera R., Asherson R.A., et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335 8705 (1990) 1541-1544
12. Nihoyannopoulos P., Gomez P.M., Joshi J., et al. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 82 2 (1990) 369-375
13. Cervera R., Font J., Pare C., et al. Cardiac disease in systemic lupus erythematosus: prospective study of 70 patients. Ann Rheum Dis 51 2 (1992) 156-159
14. Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 114 5-6 (2004) 501-507
15. Turiel M., Muzzupappa S., Gottardi B., et al. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 9 6 (2000) 406-412
16. Nesher G., Ilany J., Rosenmann D., et al. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 27 1 (1997) 27-35
17. Roldan C.A., Shively B.K., Lau C.C., et al. Systemic lupus erythematosus valve disease by transesophageal echocardiography and the role of antiphospholipid antibodies. J Am Coll Cardiol 20 5 (1992) 1127-1134
18. Cervera R., Khamashta M.A., Font J., et al. High prevalence of significant heart valve lesions in patients with the "primary" antiphospholipid syndrome. Lupus 1 1 (1991) 43-47
19. Galve E., Ordi J., Barquinero J., et al. Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med 116 4 (1992) 293-298
20. Erdogan D., Goren M.T., Diz-Kucukkaya R., et al. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke 36 3 (2005) 592-596
21. Ziporen L., Goldberg I., Arad M., et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 5 3 (1996) 196-205
22. Espinola-Zavaleta N., Vargas-Barron J., Colmenares-Galvis T., et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 137 5 (1999) 973-978
23. Amital H., Langevitz P., Levy Y., et al. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin Exp Rheumatol 17 1 (1999) 99-102
24. Afek A., Shoenfeld Y., Manor R., et al. Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Lupus 8 7 (1999) 502-507
25. Binstadt BA, Nguyen LT, Huang H, et al. Spontaneous cardiac valve inflammation in the K/BxN murine arthritis model. In: European Workshop for Rheumatology Research in Crete Session III, Abstract 70, February 24, 2006.
26. Shoenfeld Y., Blank M., Cervera R., et al. Infectious origin of the antiphospholipid syndrome. Ann Rheum Dis 65 1 (2006) 2-6
27. Blank M., Shani A., Goldberg I., et al. Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection. Thromb Res 114 5-6 (2004) 589-592
28. Qaddoura F., Connolly H., Grogan M., et al. Valve morphology in antiphospholipid antibody syndrome: echocardiographic features. Echocardiography 22 3 (2005) 255-259
29. Turiel M., Sarzi-Puttini P., Peretti R., et al. Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. Am J Cardiol 96 4 (2005) 574-579
30. Shahian D.M., Labib S.B., and Schneebaum A.B. Etiology and management of chronic valve disease in antiphospholipid antibody syndrome and systemic lupus erythematosus. J Card Surg 10 2 (1995) 133-139
31. Erkan D., Yazici Y., Sobel R., et al. Primary antiphospholipid syndrome: functional outcome after 10 years. J Rheumatol 27 12 (2000) 2817-2821
32. Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Impact of antiphospholipid antibodies on cardiovascular disease in systemic lupus erythematosus. Submitted for publication.
33. Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Impact of antiphospholipid antibodies and inflammatory markers on valvular disease in systemic lupus erythematosus. Submitted for publication.
34. Berkun Y., Elami A., Meir K., et al. Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery. J Thorac Cardiovasc Surg 127 2 (2004) 414-420
35. Doria A., and Sarzi-Puttini P. Heart, rheumatism and autoimmunity: an old intriguing link. Lupus 14 9 (2005) 643-645
36. Manzi S., Meilahn E.N., Rairie J.E., et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 5 (1997) 408-415
37. Roman M.J., Salmon J.E., Sobel R., et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am J Cardiol 87 5 (2001) 663-666
38. Doria A., Sherer Y., Meroni P.L., et al. Inflammation and accelerated atherosclerosis: basic mechanisms. Rheum Dis Clin North Am 31 2 (2005) 355-362
39. Rattazzi M., Faggin E., Bertipaglia B., et al. Innate immunity and atherogenesis. Lupus 14 9 (2005) 747-751
40. Matsuura E., Kobayashi K., Inoue K., et al. Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 14 9 (2005) 736-741
41. Mandal K., Foteinos G., Jahangiri M., et al. Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus 14 9 (2005) 742-746
42. George J., Harats D., Gilburd B., et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 99 17 (1999) 2227-2230
43. Matsuura E., and Lopez L.R. Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis?. Clin Dev Immunol 11 2 (2004) 103-111
44. Ames P.R., Margarita A., Sokoll K.B., et al. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 64 2 (2005) 315-317
45. Delgado Alves J., Mason L.J., Ames P.R., et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology (Oxford) 44 10 (2005) 1238-1244
46. Petri M. Hopkins lupus cohort. 1999 update. Rheum Dis Clin North Am 26 2 (2000) 199-213
47. Roman M.J., Shanker B.A., Davis A., et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349 25 (2003) 2399-2406
48. Baron M.A., Khamashta M.A., Hughes G.R., et al. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 64 1 (2005) 144-146
49. Ames P.R., Margarita A., Delgado Alves J., et al. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11 4 (2002) 208-214
50. Medina G., Casaos D., Jara L.J., et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 62 7 (2003) 607-610
51. Vaarala O., Manttari M., Manninen V., et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 91 (1995) 23-27
52. Hamsten A., Norberg R., Bjorkholm M., et al. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1 (1986) 113-116
53. Bili A., Moss A.J., Francis C.W., et al. Anticardiolipin antibodies and recurrent coronary events. A prospective study of 1150 patients. Circulation 102 (2000) 1258-1263
54. Sletnes K.E., Smith P., Abdelnoor M., et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet 339 8791 (1992) 451-453
55. De Caterina R., d'Ascanio A., Mazzone A., et al. Prevalence of anticardiolipin antibodies in coronary artery disease. Am J Cardiol 65 13 (1990) 922-923
56. Ferrara D.E., Liu X., Espinola R.G., et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 48 11 (2003) 3272-3279
57. Riboldi P., Gerosa M., and Meroni P.L. Statins and autoimmune diseases. Lupus 14 9 (2005) 765-768
58. Tektonidou M.G., Ioannidis J.P., Moyssakis I., et al. Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. Ann Rheum Dis 60 1 (2001) 43-48
59. Coudray N., de Zuttere D., Bletry O., et al. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br Heart J 74 5 (1995) 531-535
60. Hasnie A.M., Stoddard M.F., Gleason C.B., et al. Diastolic dysfunction is a feature of the antiphospholipid syndrome. Am Heart J 129 5 (1995) 1009-1013
61. Leung W.H., Wong K.L., Lau C.P., et al. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 89 4 (1990) 411-419
62. Asherson R.A., Cervera R., Piette J.C., et al. Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77 3 (1998) 195-207
63. Granel B., Garcia E., Serratrice J., et al. Asymptomatic intracardiac thrombi and primary antiphospholipid syndrome. Cardiology 92 1 (1999) 65-67
64. Erkan D., Erel H., Yazici Y., et al. The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. J Rheumatol 29 12 (2002) 2658-2659
65. Espinosa G., Cervera R., Font J., et al. The lung in the antiphospholipid syndrome. Ann Rheum Dis 61 3 (2002) 195-198
66. McMillan E., Martin W.L., Waugh J., et al. Management of pregnancy in women with pulmonary hypertension secondary to SLE and anti-phospholipid syndrome. Lupus 11 6 (2002) 392-398
67. McLaughlin V.V., Genthner D.E., Panella M.M., et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 130 9 (1999) 740-743
68. Ciocca R.G., Choi J., and Graham A.M. Antiphospholipid antibodies lead to increased risk in cardiovascular surgery. Am J Surg 170 2 (1995) 198-200
69. Erkan D., Leibowitz E., Berman J., et al. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol 29 4 (2002) 843-849
70. East C.J., Clements F., Mathew J., et al. Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. Anesth Analg 90 5 (2000) 1098-1101